- Home
- MRM vs EDSA Comparison
MRM vs EDSA Comparison
Compare MRM & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | EDSA |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | Japan | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 7.5M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MRM | EDSA |
|---|---|---|
| Price | $1.18 | $6.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 23.5K | ★ 315.9K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.60 | $0.72 |
| 52 Week High | $4.45 | $9.37 |
Technical Indicators
Market Signals| Indicator | MRM | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 62.35 |
| Support Level | $1.19 | $1.41 |
| Resistance Level | $1.64 | $9.06 |
| Average True Range (ATR) | 0.05 | 0.71 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 85.71 | 96.60 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.